Please use this identifier to cite or link to this item:
Title: Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients
Authors: Emori, Christini Takemi [UNIFESP]
Perez, Renata de Mello [UNIFESP]
Matos, Carla Adriana Loureiro de [UNIFESP]
Uehara, Silvia Naomi de Oliveira [UNIFESP]
Pereira, Patrícia da Silva Fucuta [UNIFESP]
Feldner, Ana Cristina de Castro Amaral [UNIFESP]
Carvalho-Filho, Roberto José de [UNIFESP]
Souza e Silva, Ivonete Sandra de [UNIFESP]
Silva, Antonio Eduardo Benedito [UNIFESP]
Ferraz, Maria Lucia Cardoso Gomes [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Rio de Janeiro (UFRJ) Internal Medicine Department
Keywords: Renal transplantation
Hepatitis B
ALT flare
Issue Date: 1-Dec-2014
Publisher: Brazilian Society of Infectious Diseases
Citation: Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 6, p. 625-630, 2014.
Abstract: Introduction: There is scarce information regarding clinical evolution of HBV infection in renal transplant patients. Aims: To evaluate the prevalence of acute exacerbation in HBV-infected renal transplant patients and its association with the time after transplantation, presence of viral replication, clinical evolution, and use of antiviral prophylaxis. Materials and methods: HBV infected renal transplant patients who underwent regular follow-up visits at 6-month intervals were included in the study. The criteria adopted to characterize exacerbation were: ALT >5 × ULN and/or >3 × baseline level. Predictive factors of exacerbation evaluated were age, gender, time on dialysis, type of donor, post-transplant time, ALT, HBeAg, HBV-DNA, HCV-RNA, immunosuppressive therapy, and use of antiviral prophylaxis. Results: 140 HBV-infected renal transplant patients were included (71% males; age 46 ±10 years; post-renal transplant time 8 ±5 years). During follow-up, 25% (35/140) of the patients presented exacerbation within 3.4 ±3 years after renal transplant. Viral replication was observed in all patients with exacerbation. Clinical and/or laboratory signs of hepatic insufficiency were present in 17% (6/35) of the patients. Three patients died as a consequence of liver failure. In univariate analysis variables associated with exacerbation were less frequent use of prophylactic/preemptive lamivudine and of mycophenolate mofetil. Lamivudine use was the only variable independently associated with exacerbation, with a protective effect. Conclusions: Acute exacerbation was a frequent and severe event in HBV-infected renal transplant patients. Prophylactic/preemptive therapy with antiviral drugs should be indicated for all HBsAg-positive renal transplant patients.
ISSN: 1413-8670
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
File Description SizeFormat 
S1413-86702014000600625.pdf518.35 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.